Tetraphase Pharmaceuticals, Inc. (TTPH) Shares Up 5.1%
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) shot up 5.1% during trading on Monday . The company traded as high as $7.24 and last traded at $7.19. 846,659 shares traded hands during trading, a decline of 33% from the average session volume of 1,262,580 shares. The stock had previously closed at $6.84.
Several equities analysts have recently issued reports on TTPH shares. BidaskClub upgraded Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, August 22nd. Zacks Investment Research upgraded shares of Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and set a $6.25 price target on the stock in a research report on Wednesday, August 9th. Needham & Company LLC reissued a “hold” rating on shares of Tetraphase Pharmaceuticals in a research note on Thursday, July 27th. ValuEngine lowered shares of Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, September 1st. Finally, Stifel Nicolaus upgraded shares of Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and boosted their price objective for the company from $8.00 to $15.00 in a report on Wednesday, July 26th. One analyst has rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $11.13.
The firm’s market capitalization is $370.13 million. The stock has a 50 day moving average of $6.63 and a 200 day moving average of $7.29.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last released its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.07). Tetraphase Pharmaceuticals had a negative net margin of 2,092.20% and a negative return on equity of 79.79%. The company had revenue of $1.59 million during the quarter, compared to the consensus estimate of $1.54 million. During the same quarter in the prior year, the firm earned ($0.47) EPS. The business’s revenue was up 28.2% compared to the same quarter last year. Analysts predict that Tetraphase Pharmaceuticals, Inc. will post ($2.54) EPS for the current fiscal year.
In other news, insider Jacques Dumas sold 17,500 shares of the firm’s stock in a transaction dated Tuesday, August 22nd. The stock was sold at an average price of $6.00, for a total value of $105,000.00. Following the completion of the sale, the insider now directly owns 17,500 shares in the company, valued at approximately $105,000. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 5.50% of the stock is currently owned by corporate insiders.
Hedge funds have recently bought and sold shares of the stock. Tekla Capital Management LLC boosted its holdings in Tetraphase Pharmaceuticals by 422.2% in the first quarter. Tekla Capital Management LLC now owns 1,004,322 shares of the biopharmaceutical company’s stock worth $9,230,000 after acquiring an additional 812,000 shares in the last quarter. Numeric Investors LLC increased its holdings in shares of Tetraphase Pharmaceuticals by 1,363.3% during the second quarter. Numeric Investors LLC now owns 754,364 shares of the biopharmaceutical company’s stock valued at $5,379,000 after acquiring an additional 702,812 shares in the last quarter. EcoR1 Capital LLC bought a new stake in shares of Tetraphase Pharmaceuticals during the second quarter valued at approximately $4,516,000. Dimensional Fund Advisors LP increased its holdings in shares of Tetraphase Pharmaceuticals by 73.6% during the second quarter. Dimensional Fund Advisors LP now owns 1,101,255 shares of the biopharmaceutical company’s stock valued at $7,853,000 after acquiring an additional 466,955 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in shares of Tetraphase Pharmaceuticals by 16.4% during the first quarter. Vanguard Group Inc. now owns 1,638,789 shares of the biopharmaceutical company’s stock valued at $15,061,000 after acquiring an additional 230,420 shares in the last quarter. 41.73% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: This article was originally posted by Watch List News and is the property of of Watch List News. If you are reading this article on another domain, it was stolen and republished in violation of United States and international copyright and trademark law. The original version of this article can be read at https://www.watchlistnews.com/tetraphase-pharmaceuticals-inc-ttph-shares-up-5-1/1607698.html.
Tetraphase Pharmaceuticals Company Profile
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.